ArticleTechnology in cancer research & treatment
Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.
Hanqing Zeng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.